lanopepden
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2008 (NCT00828867)
Timeline
Indications
Studied for
Mechanism of action
- Topoisomerase IVINHIBITOR
Topoisomerase IV inhibitor
- DNA gyraseINHIBITOR
DNA gyrase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)c(F)c(N2CCN3CCOC[C@@H]3C2)n1- Mol. weight
- 479.56 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301608 ↗
- ChEMBLCHEMBL3301616 ↗
Also known as
- gsk1322322
- gsk1322322
- gsk1322322b
- gsk1322322b
- gsk1322322j
- gsk1322322j
- gsk1322322j
- lanopepden
- lanopepden
- lanopepden
- lanopepden mesylate
- lanopepden mesylate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01953809 | Phase 1 | Aug 1, 2014 | GlaxoSmithKline |
| NCT01803399 | Phase 1 | Aug 1, 2014 | GlaxoSmithKline |
| NCT01818011 | Phase 1 | Aug 7, 2013 | GlaxoSmithKline |
| NCT01663389 | Phase 1 | Aug 10, 2012 | GlaxoSmithKline |
| NCT01648179 | Phase 1 | Mar 1, 2012 | GlaxoSmithKline |
| NCT01610388 | Phase 1 | Sep 13, 2011 | GlaxoSmithKline |
| NCT01209078 | Phase 2 | Aug 1, 2010 | GlaxoSmithKline |
| NCT00896558 | Phase 1 | May 11, 2009 | GlaxoSmithKline |
| NCT00924911 | Phase 1 | Apr 1, 2009 | GlaxoSmithKline |
| NCT00828867 | Phase 1 | Nov 14, 2008 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 2 | 2008 |
1 organizations
Page 1 / 1